Condition (MeSH)
Lassa Fever
ClinicalTrials.gov lists 19 trials for Lassa Fever or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Lassa Fever itself; the rest are tagged with a narrower condition beneath it.
When did Lassa Fever trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 2 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 5 |
| 2018 | 1 |
| 2014 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lassa Fever trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Observational | 6 |
How many Lassa Fever trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 9 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lassa Fever trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bernhard Nocht Institute for Tropical Medicine | 2 |
| Inovio Pharmaceuticals | 2 |
| International AIDS Vaccine Initiative | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Arisan Therapeutics, Inc. | 1 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Lassa Fever? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| AVIGAN | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ribavirine | 6 |
| Dexamethasone/Dexamethasone acetate | 2 |
| INO-4500 | 2 |
| HDCV Comparator | 1 |
| Day 1 Higher Dose (1×107 pfu) | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Lassa Fever? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate. | The New England journal of medicine | 2025 | Yes |
| Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults. | Frontiers in immunology | 2025 | Yes |
| Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial. | Lancet (London, England) | 2023 | Yes |
| Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE). | Travel medicine and infectious disease | 2020 | Yes |
| Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali. | PLoS neglected tropical diseases | 2013 | Yes |
Showing 5 of 9 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Lassa fever | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Lassa fever | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Lassa fever | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
| Lassa fever | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Lassa fever | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Lassa fever | 99824 | Exact | Orphadata Science knowledge files, Product 1 |
| Lassa fever | 99824 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.